Literature DB >> 27000990

Application of CRISPR-mediated genome engineering in cancer research.

Volkan I Sayin1, Thales Papagiannakopoulos2.   

Abstract

Cancer is a multistep process that arises from a series of genetic and epigenetic events. With recent technological advances there has been a burst in genome sequencing and epigenetic studies revealing a plethora of alterations that may contribute to cancer. However, the great challenge for the cancer research community is the systematic functional characterization of these genetic and epigenetic events to assess their role in cancer initiation and progression. Recent advances in genome engineering using CRISPR/Cas9, an ancient bacterial immune-like system, have revolutionized cancer genetics. Here we highlight the breakthroughs in the effective use of these novel genome-editing techniques, and we discuss the challenges and potential applications of these tools for cancer biology.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CRISPR; Cancer; Cas9; Genome engineering; Mouse models

Mesh:

Year:  2016        PMID: 27000990     DOI: 10.1016/j.canlet.2016.03.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

2.  Circadian Rhythm Disruption Promotes Lung Tumorigenesis.

Authors:  Thales Papagiannakopoulos; Matthew R Bauer; Shawn M Davidson; Megan Heimann; Lakshmipriya Subbaraj; Arjun Bhutkar; Jordan Bartlebaugh; Matthew G Vander Heiden; Tyler Jacks
Journal:  Cell Metab       Date:  2016-07-28       Impact factor: 27.287

Review 3.  Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer.

Authors:  Narmadhaa Siva; Sonal Gupta; Ayam Gupta; Jayendra Nath Shukla; Babita Malik; Nidhi Shukla
Journal:  3 Biotech       Date:  2021-02-26       Impact factor: 2.406

Review 4.  Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine.

Authors:  Xiaofeng Dai; Pilar Blancafort; Peiyu Wang; Agustin Sgro; Erik W Thompson; Kostya Ken Ostrikov
Journal:  Adv Sci (Weinh)       Date:  2020-04-23       Impact factor: 16.806

Review 5.  Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.

Authors:  Huimin Kong; Enguo Ju; Ke Yi; Weiguo Xu; Yeh-Hsing Lao; Du Cheng; Qi Zhang; Yu Tao; Mingqiang Li; Jianxun Ding
Journal:  Adv Sci (Weinh)       Date:  2021-10-19       Impact factor: 16.806

Review 6.  Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.

Authors:  Talha Bin Emran; Asif Shahriar; Aar Rafi Mahmud; Tanjilur Rahman; Mehedy Hasan Abir; Mohd Faijanur-Rob Siddiquee; Hossain Ahmed; Nova Rahman; Firzan Nainu; Elly Wahyudin; Saikat Mitra; Kuldeep Dhama; Mahmoud M Habiballah; Shafiul Haque; Ariful Islam; Mohammad Mahmudul Hassan
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

7.  Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer.

Authors:  Volkan I Sayin; Sarah E LeBoeuf; Simranjit X Singh; Shawn M Davidson; Douglas Biancur; Betul S Guzelhan; Samantha W Alvarez; Warren L Wu; Triantafyllia R Karakousi; Anastasia Maria Zavitsanou; Julian Ubriaco; Alexander Muir; Dimitris Karagiannis; Patrick J Morris; Craig J Thomas; Richard Possemato; Matthew G Vander Heiden; Thales Papagiannakopoulos
Journal:  Elife       Date:  2017-10-02       Impact factor: 8.140

Review 8.  CRISPR therapeutic tools for complex genetic disorders and cancer (Review).

Authors:  Stella Baliou; Maria Adamaki; Anthony M Kyriakopoulos; Demetrios A Spandidos; Mihalis Panayiotidis; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Oncol       Date:  2018-06-06       Impact factor: 5.650

Review 9.  CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical Trials.

Authors:  Khalil Khalaf; Krzysztof Janowicz; Marta Dyszkiewicz-Konwińska; Greg Hutchings; Claudia Dompe; Lisa Moncrieff; Maurycy Jankowski; Marta Machnik; Urszula Oleksiewicz; Ievgeniia Kocherova; Jim Petitte; Paul Mozdziak; Jamil A Shibli; Dariusz Iżycki; Małgorzata Józkowiak; Hanna Piotrowska-Kempisty; Mariusz T Skowroński; Paweł Antosik; Bartosz Kempisty
Journal:  Genes (Basel)       Date:  2020-08-11       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.